Search Within

Dmitriy Zamarin

Formats
  1. Journal Article (101)
  2. Meeting Abstract (85)
  3. Editorial (7)
  4. Guidelines (3)
  5. Review (3)
  6. Book Section (2)
Groups
  1. Department of Medicine (201)
  2. GDMT, Medicine (201)
  3. Gynecologic Medicine Service (201)
  4. Gynecology Disease Management Team (201)
  5. Solid Tumor Oncology Division (201)
  6. GSK Faculty (75)

More Groups

People
  1. Carol Aghajanian (60)
  2. Britta Weigelt (50)
  3. Roisin O'Cearbhaill (42)
  4. Claire Friedman (40)
  5. Jedd Wolchok (34)
  6. Nadeem Abu-Rustum (34)

More People

Years
  1. 2024 (8)
  2. 2023 (18)
  3. 2022 (40)
  4. 2021 (16)
  5. 2020 (43)
  6. 2019 (14)

More Years

Publications
  1. Gynecologic Oncology (35)
  2. Journal of Clinical Oncology (24)
  3. Journal for ImmunoTherapy of Cancer (20)
  4. Cancer Research (13)
  5. Clinical Cancer Research (11)
  6. International Journal of Gynecological Cancer (9)

More Publications

Publishers
  1. Elsevier Inc. (37)
  2. American Association for Cancer Research (32)
  3. American Society of Clinical Oncology (29)
  4. Biomed Central Ltd (20)
  5. Nature Publishing Group (20)
  6. Lippincott Williams & Wilkins (11)

More Publishers

Results (201)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
    Journal Article

    Oseledchyk, A.; Ricca, J. M.; Gigoux, M.; Ko, B.; Redelman-Sidi, G.; Walther, T.; Liu, C.; Iyer, G.; Merghoub, T.; Wolchok, J. D.; more...
    Oncotarget (2018)

    Fulltext@MSK | Save
  • Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy
    Journal Article

    Ricca, J. M.; Oseledchyk, A.; Walther, T.; Liu, C.; Mangarin, L.; Merghoub, T.; Wolchok, J. D.; Zamarin, D.
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
    Journal Article

    Zamarin, D.; Ricca, J. M.; Sadekova, S.; Oseledchyk, A.; Yu, Y.; Blumenschein, W. M.; Wong, J.; Gigoux, M.; Merghoub, T.; Wolchok, J. D.
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Vanadium: A panacea for resistance to oncolytic immunotherapy?
    Journal Article

    Zamarin, D.
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells
    Journal Article

    Dai, P.; Wang, W.; Yang, N.; Serna-Tamayo, C.; Ricca, J. M.; Zamarin, D.; Shuman, S.; Merghoub, T.; Wolchok, J. D.; Deng, L.
    Science Immunology (2017)

    Fulltext@MSK | Save
  • Early clinical progression in patients with gynecologic malignancies receiving immunomodulatory antibody therapy
    Meeting Abstract

    Zamarin, D.; Martin, M.; Zecca, N.; Iasonos, A.; Zhou, Q.; Aghajanian, C.; Sabbatini, P.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma
    Meeting Abstract

    Konner, J. A.; Boucicaut, N. N.; O'Cearbhaill, R. E.; Zamarin, D.; Makker, V.; Sabbatini, P.; Tew, W. P.; Cadoo, K. A.; Grisham, R. N.; Aghajanian, C.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
    Meeting Abstract

    Zamarin, D.; Ricca, J.; Oseledchyk, A.; Gigoux, M.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save